Moreover, given that we are beginning to understand the clinical relevance of elevated agrin expression and mechanisms behind agrin-YAP regulation, targeting agrin through function blocking antibodies holds great promise as additional HCC therapy (Figure 5). This evidence concerns the gene AGRN and hepatocellular carcinoma.